the expert in the sector is capable of determining the active ingredient in the therapy of La Peyronie's disease on the basis of his or her general knowledge, such as, for example, the above-cited report by Belgrano and the literature cited in this patent application
This scenario may arise when doctors experience uncertainty or apprehension about their assessment, potentially leading to ME/CFS patients feeling neglected
*Correspondence: Pedro Grandes, [email protected] These authors have contributed equally to this work and share last authorship This article was submitted to Nutrition, Psychology and Brain Health, a section of the journal Frontiers in Nutrition Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
5-CTATTGGTCGCACTATGGGC-3 (site 798811, mouse CRT promoter)
WEIDELL, William Peter WEIER, Bernard Arthur WELCH, William Edward WELLER, Ludwig Fredrick WELLS, Alfred Floyd WELLS, Floyd Arthur WELLS, Harvey Anthony WELLS, Raymond Virgil Jr